Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05169437|
Recruitment Status : Recruiting
First Posted : December 27, 2021
Last Update Posted : May 6, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumor Breast Tumor Colon Tumor, Malignant Lung Tumor Urologic Cancer Pancreatic Cancer Melanoma Metastatic Cancer Locally Advanced Solid Tumor Esophageal Cancer Endometrial Cancer Head and Neck Cancer||Drug: Niraparib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations|
|Actual Study Start Date :||March 15, 2022|
|Estimated Primary Completion Date :||June 1, 2024|
|Estimated Study Completion Date :||July 1, 2025|
|Experimental: Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations||
Eligible participants will receive daily dosing of Niraparib.
Other Name: Zejula
- Overall Response Rate (ORR) - Independent Central Review (ICR) [ Time Frame: Up to 4 years ]To evaluate overall response rate (ORR) as assessed by Independent Central Review (ICR) using RECIST v1.1
- Duration of Response (DOR) - Independent Central Review (ICR) [ Time Frame: Up to 4 years ]To evaluate duration of response (DOR) as assessed by ICR using RECIST v1.1
- Progression-Free Survival (PFS) - Independent Central Review (ICR) [ Time Frame: Up to 4 years ]To evaluate progression-free survival (PFS) as assessed by ICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
- Overall Response Rate (ORR) - Investigator [ Time Frame: Up to 4 years ]To evaluate ORR as assessed by Investigator using RECIST v1.1
- Duration of Response (DOR) - Investigator [ Time Frame: Up to 4 years ]To evaluate DOR as assessed by Investigator using RECIST v1.1
- Progression-Free Survival (PFS) - Investigator [ Time Frame: Up to 4 years ]To evaluate PFS as assessed by Investigator using RECIST v1.1
- Clinical Benefit Rate (CBR) - Investigator and ICR [ Time Frame: Up to 4 years ]To evaluate Clinical Benefit Rate (CBR) as assessed by ICR and Investigator
- ORR with untreated measurable CNS lesions - Investigator [ Time Frame: Up to 4 years ]To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by Investigator using RECIST v1.1
- ORR with untreated measurable CNS lesions - ICR [ Time Frame: Up to 4 years ]To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by ICR using RECIST v1.1
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) [ Time Frame: Up to 4 years ]To evaluate safety and tolerability per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)
- Overall Survival (OS) [ Time Frame: Up to 4 years ]To evaluate overall survival (OS)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Participants must be at least 18 years of age or older.
- Participants must have a histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor(s).
- Participants must have tested positive for a pathogenic or likely pathogenic tPALB2 gene mutation using a CLIA-certified laboratory as described in the Next-Generation Sequencing (NGS) Laboratory Manual.
- Participants who have stable and asymptomatic Central Nervous System (CNS) disease must be receiving a stable (for at least 7 days) or decreasing corticosteroid dose at the time of study entry.
- Participants must submit fresh or archived (collected within 24 months of enrollment) Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample to the central laboratory for post-enrollment confirmation of tPALB2 status.
- Participants must have received all standard therapies appropriate for their tumor type and stage of disease or, in the opinion of the Investigator, the patient would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy, or the participant has no satisfactory alternative treatments.
- Participants have other active concomitant malignancy that warrants systemic, biologic, or hormonal therapy.
- Participants who have ovarian or prostate cancer.
- Participants who have variants of undetermined significance (VUS), but not pathogenic variants of PALB2, at the time of screening.
- Participants who relapsed while receiving platinum based therapy in the adjuvant/curative setting.
- Participants progressing within 14-18 weeks while receiving platinum based therapy in the metastatic setting.
- Participants who have received Poly (ADP-ribose) polymerase (PARP) inhibitor(s) in prior lines of treatment.
- Participants with leptomeningeal disease, carcinomatous meningitis, symptomatic brain metastases, or radiologic signs of CNS hemorrhage.
- Participants with germline or somatic BRCA1 or BRCA2 mutations.
- Participant has systolic blood pressure (BP) over 140 mmHg or diastolic BP over 90 mmHg, despite optimal medical therapy.
- Participants have previously or are currently participating in a treatment study of an investigational agent within 3 weeks of the first dose of therapy preceding the study.
- Participants have received prior systemic cytotoxic chemotherapy, biological therapy, or hormonal therapy for cancer, or received radiation therapy within 3 weeks of the first dose therapy preceding the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05169437
|Contact: Brad Johnson||(630)firstname.lastname@example.org|
|Contact: Anjali Avadhani, MDemail@example.com|
|Study Director:||Anjali Avadhani, MD||Tempus Labs, Inc.|
|Responsible Party:||Tempus Labs|
|Other Study ID Numbers:||
IND Number: 159142 ( Other Identifier: FDA )
|First Posted:||December 27, 2021 Key Record Dates|
|Last Update Posted:||May 6, 2023|
|Last Verified:||May 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Metastatic Solid Tumor
Locally Advanced Solid Tumor
Advanced Solid Tumor
Local Solid Tumor
Head and Neck Cancer
Head and Neck Neoplasms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Endocrine System Diseases
Genital Neoplasms, Female